Gossamer Bio, Inc. (NASDAQ:GOSS) Sees Significant Drop in Short Interest

Gossamer Bio, Inc. (NASDAQ:GOSS) was the recipient of a large drop in short interest during the month of December. As of December 31st, there was short interest totalling 6,120,000 shares, a drop of 12.8% from the December 15th total of 7,020,000 shares. Based on an average daily volume of 1,330,000 shares, the short-interest ratio is currently 4.6 days.

Gossamer Bio Stock Down 3.8 %

Shares of NASDAQ GOSS traded down $0.04 during midday trading on Friday, hitting $0.96. The company’s stock had a trading volume of 817,985 shares, compared to its average volume of 1,082,774. The company has a debt-to-equity ratio of 3.64, a current ratio of 6.74 and a quick ratio of 6.74. The firm has a market capitalization of $217.97 million, a price-to-earnings ratio of -3.01 and a beta of 1.81. The business’s fifty day simple moving average is $0.84 and its two-hundred day simple moving average is $0.91. Gossamer Bio has a 1 year low of $0.50 and a 1 year high of $1.60.

Gossamer Bio (NASDAQ:GOSS) last released its earnings results on Thursday, November 7th. The company reported ($0.14) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.18) by $0.04. The business had revenue of $9.48 million for the quarter, compared to analyst estimates of $4.52 million. On average, equities analysts predict that Gossamer Bio will post -0.28 EPS for the current year.

Wall Street Analyst Weigh In

Separately, HC Wainwright restated a “buy” rating and set a $10.00 price target on shares of Gossamer Bio in a research note on Monday, November 11th. Five research analysts have rated the stock with a buy rating, According to data from MarketBeat, Gossamer Bio presently has a consensus rating of “Buy” and a consensus target price of $9.20.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently bought and sold shares of GOSS. Sequoia Financial Advisors LLC increased its holdings in Gossamer Bio by 26.7% during the 3rd quarter. Sequoia Financial Advisors LLC now owns 118,500 shares of the company’s stock worth $117,000 after purchasing an additional 25,000 shares during the period. US Bancorp DE acquired a new position in shares of Gossamer Bio during the third quarter worth about $39,000. Choreo LLC purchased a new stake in shares of Gossamer Bio during the second quarter worth approximately $46,000. GSA Capital Partners LLP purchased a new position in Gossamer Bio in the third quarter worth approximately $67,000. Finally, The Manufacturers Life Insurance Company grew its holdings in Gossamer Bio by 24.2% during the 3rd quarter. The Manufacturers Life Insurance Company now owns 385,133 shares of the company’s stock worth $380,000 after acquiring an additional 74,920 shares in the last quarter. 81.23% of the stock is currently owned by hedge funds and other institutional investors.

About Gossamer Bio

Gossamer Bio, Inc, a clinical-stage biopharmaceutical company, focuses on developing and commercializing seralutinib for the treatment of pulmonary arterial hypertension (PAH) in the United States. The company is developing GB002, an inhaled, small molecule, platelet-derived growth factor receptor, or PDGFR, colony-stimulatin factor 1 receptor and c-KIT inhibitor, which is in Phase 3 clinical trial for the treatment of PAH.